Evidence map›Paper›PMID 34920248›Full record

ArticleMultiple sclerosis and related disorders2022

Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod.

Magdalena Krbot Skorić, Dunja Rogić, Ivana Lapić, Dragana Šegulja, Mario Habek

Open access · bronzeAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis and related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Magdalena Krbot SkorićDepartment of Neurology, University Hospital Center Zagreb, Zagreb, Croatia; Faculty of Electrical Engineering and Computing, University of Zagreb, Zagreb, Croatia.
Dunja RogićClinical Institute for Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia. Electronic address: predstojnik.lab@kbc-zagreb.hr.
Ivana LapićClinical Institute for Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia. Electronic address: ilapic@kbc-zagreb.hr.
Dragana ŠeguljaClinical Institute for Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia. Electronic address: dsegulja@kbc-zagreb.hr.
Mario HabekDepartment of Neurology, University Hospital Center Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia. Electronic address: mhabek@mef.hr.
University Hospital Centre Zagreb · HRUniversity of Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study is to determine a development of humoral response after COVID-19 vaccination in persons with secondary progressive multiple sclerosis (pwSPMS) on siponimod, compared to healthy controls (HC).

methodsIn 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was performed after vaccination against COVID-19.

resultspwSPMS taking siponimod had a significantly lower titer of SARS-CoV2 antibodies compared to healthy controls (19.4 (0-250) vs. 250 (250), p>0.001). Two (15.4%) pwSPMS on siponimod had unmeasurable titers of SARS-CoV2-2 antibodies, while all HC had positive titers.

conclusionAlthough the results of this study are limited by a small sample size, results have consistently shown low titers of SARS-CoV-2 IgG after COVID-19 vaccinations in pwSPMS on siponimod.

Indexed as

COVID-19Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveAntibodies, ViralAzetidinesBenzyl CompoundsBNT162 VaccineCOVID-19 VaccinesHumansImmunity, HumoralRNA, ViralSARS-CoV-2VaccinationAntibodies, ViralAzetidinesBenzyl CompoundsBNT162 VaccineCOVID-19 VaccinesRNA, ViralsiponimodCOVID-19SARS-CoV-2 IgG antibodySecondary progressive multiple sclerosisSiponimodVaccines

Identifiers

PMID34920248
PMCPMC8629510
OpenAlexW3216972626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.